Skip to main content
PGIM Quantitative Solutions LogoPGIM Quantitative Solutions Logo
  • About Us
    • Our Philosophy
    • Our History
    • The Team
    • Diversity, Equity & Inclusion
    • Contact Us
  • All Insights
    • ESG
    • Market Views
  • ESG Overview
    • ESG Insights
    • ESG Policy
    • Stewardship and Governance
  • Overview of Solutions
    • Quantitative Equity
    • Multi Asset
    • PGIM Wadhwani
    • PGIM DC Solutions
  • Client Log In
  • Careers
QMA Global Multi-Asset
Market Views

The Battle of the Vs: Virus Versus VaccineTheBattleoftheVs:VirusVersusVaccine

Dec 15, 2020

5 mins

Share
  • Mail
  • LinkedIn
  • Twitter
  • Copy URL
Download PDF

Share

On the December PGIM Global Partners CIO call hosted by QMA, chief investment officers and senior investment professionals from PGIM's international businesses, PGIM Fixed Income and QMA discussed the outlook for markets and the global economy to year end and the prospects for 2021. In the near term, the battle of the “Vs,” the tug of war between virus and vaccine, is likely to be the dominant theme as the positive news about vaccine development is offset by the second wave of the Covid-19 virus with rising infections, hospitalizations and deaths and the attendant risks to economic activity.

A successful vaccine has been developed in record time, less than one year. The previous record for the fastest time to develop a vaccine occurred in the late 1960s when it took four years to develop a vaccine for the mumps. Currently, three firms, Pfizer/BioNTech, Moderna and AztraZeneca reported that their vaccines showed over 90% success in final clinical trials. The FDA is likely to approve the Pfizer/BioNTech and Moderna vaccines in in December. Based on comments from the European Commission President, the European Medicines Agency is likely to authorize the three leading vaccines by year-end. The UK became the first country to authorize the Pfizer/BioNtech vaccine, and the companies have said that they are ready to deliver the first doses to the UK immediately.

QMA Portfolio Manager Ed Keon, Robert Tipp, chief investment strategist at PGIM Fixed Income, and Ellen Gaske, PGIM Fixed Income’s lead economist for G-10 countries, all agreed that the vaccine progress was a significant positive development, though there are still questions about FDA approval, mass production, storage and distribution. However, Goldman Sachs, in a recent report, said its baseline forecast "is that large shares of the population are vaccinated by the end of Q2 2021 in all major DMs [developed markets]. The UK is expected to vaccinate 50% of its population in March, with the US and Canada following in April.” According to the Goldman forecast, “the EU, Japan, and Australia reach this 50% threshold in May. As production becomes abundant by mid-Q2, vaccination rises gradually with demand and surpasses 70% across all DMs in the fall when children become eligible." Hence, markets seem to be optimistic that the end of the Covid-19 pandemic and a return to normalcy is a now matter of months, not years.

However, the vaccine optimism is tempered by concerns about rising virus cases, hospitalizations and deaths. The current wave of infections has prompted renewed lockdowns and restrictions on activity in the US, Europe and several other countries. Consequently, after the strong GDP rebound in Q3, economic activity is on track to slow in Q4, and the weakness is likely to drag into Q1 2021 as the vaccine is unlikely to be widely distributed until mid-2021. US GDP growth is expected to moderate into the 3%-to-5% range in Q4, but, as Gaske noted, there are risks to Q1 growth, namely lingering effects of the lockdowns and winter seasonality. In Europe, growth is expected to dip back into negative territory in Q4, and Gaske is looking for a W-shaped recovery in Europe.

Given the vaccine-virus cross currents, the big question, according to Keon, is whether the US Congress can agree on a stimulus package, which could provide a financial bridge into mid-2021 by which time a sufficiently large number of people are vaccinated. There appears to be some chance of a stimulus package of between $500 billion and $900 billion, which could help the nation get through the next few months before mass vaccinations.

Looking beyond the vaccine-virus cross currents in the near-term, the December call participants expressed optimism about prospects for a solid economic rebound in 2021, with easing of political uncertainties, pent-up demand unleashed by the reopening of economic activity, strong tail winds from fiscal and monetary stimulus and low interest rates. The economic recovery and strong earnings rebound are expected to fuel solid stock market gains in 2021.

The end of US political uncertainty and prospects for a divided government mean some of the less-market friendly parts of the Biden agenda, like tax hikes on individuals and corporations and regulatory overreach, are unlikely. Another near-term positive is the easing of Brexit uncertainty, with increased odds of a last-minute UK-EU deal, which could avert a “hard” Brexit.

The Global Economy Poised to Rebound

With vaccine approval, production and mass distribution in the offing, economies are on track to reopen and normalize. Given pent-up demand, the global economy is slated for a robust rebound in 2021. Fresh fiscal stimulus and further monetary stimulus is likely to provide fuel for the recovery. While a divided government means fiscal stimulus in the US is likely to be more modest than under a “Blue Wave” scenario, fiscal stimulus in Europe, Japan and several emerging markets economies is likely to be significant. Paolo Mazzocca, an analyst at Pramerica Italy SGR, pointed out that the Italian team is looking for further fiscal stimulus in 2021. Seiji Maruyama, the chief investment officer of PGIM Japan, indicated that the Suga administration is compiling a third supplementary budget to finance fresh economic stimulus, so the Japanese recovery would not lose steam amid the fresh wave of COVID infections. The recovery is also likely to be supported by low interest rates. Tipp expects the US 10-year yield to remain in a 0.7-1% range and yields in Europe, Japan and other markets to remain around current lows.

Global GDP growth is expected to be in the 5%-to-6% range in 2021 after contracting around -4% in 2020. The US economy is expected to fire on all cylinders with solid consumer spending, a rebound in capital expenditures, red-hot housing and inventory rebuilding. With the economy growing at a solid, above potential pace, job growth should continue and unemployment should decline, reducing the slack in the labor market. Gaske’s forecast is for US GDP to grow around 4.5% in 2021, with risks to the upside. This is above the consensus forecast of around 4%, after contracting around -3.5% in 2020. Gaske also anticipates that as the vaccines are rolled out, there is likely to be a rotation from spending on goods to increased expenditures on services, boosted by pent-up demand for services.

Among other countries/regions, Eurozone GDP is expected to grow around 4.6% in 2021 after the sharp -7% contraction in 2020. Given the deep hole in 2020, Mazzoca and the Italian team expect the Eurozone economies to return to pre-COVID-19 levels only by 2022. The UK economy, which suffered one of the sharpest declines in 2020, with growth estimated to have contracted by -11.2%, is on track to a strong rebound in 2021 with over 5% GDP growth. The Japanese economy is expected to grow by around 2.5% in 2021. In China, the first country to recover from the pandemic and the only country to post positive growth in 2020, around 2%, growth is expected to strengthen further in 2021 to around 8%. Bevan Yeh, the equity chief investment officer at PGIM SITE expects Taiwan’s economy to grow around 4% in 2021. PGIM India’s chief investment officers, Srinivas Ravoori and Kumaresh Ramakrishnan, expect India to re-emerge as one of the fastest-growing emerging markets, with a double-digit GDP rebound in 2021 after contracting -9% in 2020.

Strong Earnings Rebound

After the collapse in corporate profits and earnings in 2020, and with GDP growth on track to a solid recovery in 2021, corporate profits are expected to rebound sharply. Consensus forecasts are for S&P earnings per share to grow between 25% to 30% in 2021, to around $175, after declining around -15% to $136 in 2020.

Earnings for Eurozone companies are expected to rebound around 50% in 2021 after the sharp -37% decline in 2020. Japanese earnings are on track to recover around +43% in 2021 after a relatively modest -9% decline in 2020. Emerging markets (EM) earnings expectations for 2020 have been improving to a modest -8% decline for 2020. EM earnings are expected to rise 32% in 2021.

The strong earnings recovery is likely to drive equity market gains in 2021 after P/E multiple expansion lifted stocks higher in 2020. Given the 2020 gains, stocks are currently on the expensive side, as P/E multiples have risen given the strong price gains and decline in earnings. Hence there is less scope for multiple expansion, and robust earnings growth is expected to fuel the rally in 2021.

The equity rally in 2020 was driven largely by stay-at-home stocks and growth sectors. Region-wise, the US, and tech-heavy Asian EMs, China, Taiwan and Korea, posted strong gains in 2020, while Europe, Japan and cyclical-oriented emerging markets lagged. In 2021, stock market gains are likely to broaden across sectors and regions.

The Bottom-line

After struggling in September and October, global stock markets enjoyed a strong rally in November with easing of US election uncertainty and significant progress on the vaccine front. The rally was broad-based with big gains in cyclical and value sectors and regions, and small caps.

With Santa Claus arriving early this year, the December CIO call participants discussed the outlook for markets and the economy to year-end 2020 and the prospects for 2021. With US election uncertainty largely over and a divided government more likely, the tug of war between the vaccine and virus is likely to be the key determinant of the market trajectory to year-end and in early 2021.

Looking beyond the near-term vaccine-virus cross currents, the December call participants expressed optimism about prospects for a solid economic rebound in 2021 with easing of political uncertainties, pent-up demand from reopening of economic activity and strong tail winds from fiscal and monetary stimulus and low interest rates. The robust economic rebound and strong earnings growth are expected to fuel further, broad-based stock market gains in 2021.

Download PDF
  • About Us

    • Overview
    • Our Philosophy
    • Our History
    • The Team
    • Inclusion & Diversity
    • Contact Us
    • Careers
  • Insights

    • Overview
    • ESG
    • Market Views
  • ESG

    • Overview
    • Insights
    • ESG Policy
    • Stewardship and Governance
  • Solutions

    • Overview
    • Quantitative Equity
    • Multi Asset
    • PGIM Wadhwani
    • PGIM DC Solutions
PGIM Quantitative Solutions Logo
  • Terms & Conditions
  • Privacy Center
  • Accessibility Help
  • Cookie Preference Center

For Professional Investors only. All investments involve risk, including the possible loss of capital.

The content and materials presented here are for informational and educational purposes only and should not be construed as investment advice or an offer or solicitation in respect of any products or services to any persons who are prohibited from receiving such information under the laws applicable to their place of citizenship, domicile or residence. PGIM Quantitative Solutions LLC (PGIM Quantitative Solutions or PGIM Quant), formerly known as QMA LLC, is an SEC-registered investment adviser and a wholly-owned subsidiary of PGIM, Inc. (PGIM), the principal asset management business of Prudential Financial, Inc. (PFI) of the United States of America. Registration with the SEC does not imply a certain level of skill or training. PFI of the United States is not affiliated in any manner with Prudential plc incorporated in the United Kingdom or with Prudential Assurance Company, a subsidiary of M&G plc, incorporated in the United Kingdom. 

In the United Kingdom, information is issued by PGIM Limited with registered office: Grand Buildings, 1-3 Strand, Trafalgar Square, London, WC2N 5HR. PGIM Limited is authorised and regulated by the Financial Conduct Authority (“FCA”) of the United Kingdom (Firm Reference Number 193418). In the European Economic Area (“EEA”), information is issued by PGIM Netherlands B.V. with registered office: Gustav Mahlerlaan 1212, 1081 LA Amsterdam, The Netherlands. PGIM Netherlands B.V. is authorised by the Autoriteit Financiële Markten (“AFM”) in the Netherlands (Registration number 15003620) and operating on the basis of a European passport. In certain EEA countries, information is, where permitted, presented by PGIM Limited in reliance of provisions, exemptions or licenses available to PGIM Limited under temporary permission arrangements following the exit of the United Kingdom from the European Union. 

These materials are issued by PGIM Limited and/or PGIM Netherlands B.V. to persons who are professional clients as defined under the rules of the FCA and/or to persons who are professional clients as defined in the relevant local implementation of Directive 2014/65/EU (MiFID II). PGIM Quantitative Solutions, PGIM Limited and/or PGIM Netherlands B.V. are indirect, wholly-owned subsidiaries of PGIM. These materials are not intended for distribution to, or use by, any person in any jurisdiction where such distribution would be contrary to local or international law or regulation.

In Japan, investment management services are made available by PGIM Japan, Co. Ltd., ("PGIM Japan"), a registered Financial Instruments Business Operator with the Financial Services Agency of Japan. In Hong Kong, information is provided by PGIM (Hong Kong) Limited, a regulated entity with the Securities & Futures Commission in Hong Kong to professional investors as defined in Section 1 of Part 1 of Schedule 1 (paragraph (a) to (i) of the Securities and Futures Ordinance (Cap.571). In Singapore, information is issued by PGIM (Singapore) Pte. Ltd. (“PGIM Singapore”), a Singapore investment manager that is licensed as a capital markets service license holder by the Monetary Authority of Singapore and an exempt financial adviser. These materials are issued by PGIM Singapore for the general information of “institutional investors” pursuant to Section 304 of the Securities and Futures Act, Chapter 289 of Singapore (the “SFA”) and “accredited investors” and other relevant persons in accordance with the conditions specified in Sections 305 of the SFA. In South Korea, information is issued by PGIM Quantitative Solutions, which is licensed to provide discretionary investment management services directly to South Korean qualified institutional investors on a cross-border basis.

PGIM, PGIM Quantitative Solutions logo and the Rock design are service marks of PFI and its related entities, registered in many jurisdictions worldwide.

© 2022 PGIM Quantitative Solutions. All Rights Reserved.
 

You are viewing this page in preview mode.

Edit Page